ADAGENE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1 STUDY OF MUZASTOTUG IN COMBINATION WITH INCYTE’S INCA33890 IN PATIENTS WITH MICROSATELLITE STABLE COLORECTAL CANCER

Reuters · 2d ago

Please log in to view news